Glycopyrrolate/ formoterol fumarate · Bevespi Aerosphere
Small molecule
Also known as PT003
Evidence outlook
Approved: Chronic Obstructive Pulmonary Disease
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
Also approved (3)
- Maintenance treatment to relieve symptoms of COPD (Bevespi Aerosphere)
- COPD maintenance treatment (Bevespi Aerosphere)
- Maintenance dual bronchodilator treatment to relieve symptoms in adult patients with COPD (pMDI)
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT03324607 NCT03324607 · COPD The study used a single treatment group without randomization, blinding, or a placebo or active comparator, and only 17 participants contributed to the primary imaging analysis. Its primary endpoints were surrogate MRI measures rather than established clinical outcomes, and the findings were mixed across those measures, so they provide limited evidence about Bevespi’s clinical effectiveness. Registry: NCT03324607 | 2/3 | Ventilation Distribution as Measured by Ventilation Defect+Low Percent (Week 2); Barrier Uptake. (2 weeks); Red Blood Cell (RBC) Uptake (2 weeks) 2019-11-12 | Ventilation Distribution as Measured by Ventilation Defect+Low Percent (Week 2): Treatment — Baseline: 57.8 percentage of total ventilation (Standard Deviation 8.4); Week 2: 52.5 percentage of total ventilation (Standard Deviation 10.6) | Weak signal | link ↗ |
View 3 more trials
NCT02343458 NCT02343458 · Chronic Obstructive Pulmonary Disease This phase 3 trial randomised 1,756 patients with moderate to very severe COPD to glycopyrronium/formoterol, formoterol alone, glycopyrronium alone or placebo by metered dose inhaler, with participants, care providers, investigators and outcome assessors masked. The primary endpoint was change from baseline in morning pre-dose trough FEV1. At week 24 the least squares mean change was 120 mL (95% CI 102 to 138) with the combination and -45 mL (95% CI -73 to -17) with placebo, with similar non-overlapping separation in the two other prespecified analysis approaches. The record posts no between-group statistical test and reports no power calculation or planned enrolment. Registry: NCT02343458 | 3 | Change From Baseline in Morning Pre-dose Trough FEV1 at Week 24 of Treatment (US/China Approach); Change From Baseline in Morning Pre-dose Trough FEV1 Over Weeks 12-24, Japan Approach; Change From Baseline in Morning Pre-dose Trough FEV1 Over 24 Weeks. Primary Endpoint, EU/SK/TW Approach, Secondary Endpoint US/China Approach. 2017-08-31 | Completed. Key figures are not recorded here; the rationale explains the result. | Partial signal | link ↗ |
PINNACLE 1 NCT01854645 · Chronic Obstructive Pulmonary Disease Registry: NCT01854645 | 3 | Change From Baseline in Morning Pre-dose Trough FEV1 at Week 24 (Baseline and at Week 24) 2015-02 | Change From Baseline in Morning Pre-dose Trough FEV1 at Week 24 (Baseline and at Week 24): GFF MDI (PT003) 0.126 Liters (95% CI 0.107 to 0.145) | GP MDI (PT001) 0.066 Liters (95% CI 0.045 to 0.087) | FF MDI (PT005) 0.062 Liters (95% CI 0.041 to 0.082) | Spiriva® Handihaler® (Open-label) 0.105 Liters (95% CI 0.084 to 0.125) | Placebo -0.024 Liters (95% CI -0.055 to 0.007) | not yet graded | link ↗ |
PINNACLE 2 NCT01854658 · Chronic Obstructive Pulmonary Disease Registry: NCT01854658 | 3 | Change From Baseline in Morning Pre-dose Trough FEV1 (At Week 24) 2015-03 | Change From Baseline in Morning Pre-dose Trough FEV1 (At Week 24): FF MDI (PT005) 0.061 Liters (95% CI 0.039 to 0.082) | GP MDI (PT001) 0.063 Liters (95% CI 0.041 to 0.084) | GFF MDI (PT003) 0.116 Liters (95% CI 0.097 to 0.136) | Placebo MDI 0.013 Liters (95% CI -0.018 to 0.044) | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (11)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1 (3)
What this study did
What this study did
What this study did
Phase 4 (1)
What this study did
Studied as part of a combination product (1)
Studies of a fixed-dose combination that contains this drug. The combination is the product under test, so these are that product's evidence rather than this one's; the link is kept because the drug really was administered.
Phase 4 (1)
What this study did
Competitive landscape
Other Beta-2 adrenergic receptor drugs
Aclidinium bromide/formoterol fumarate, albuterol (Armstrong Albuterol HFA), albuterol (Ventolin), albuterol / budesonide, albuterol sulfate (Amphastar) and 11 more. Compare all 17 Beta-2 adrenergic receptor drugs
Other Muscarinic acetylcholine receptor (M3) drugs
Aclidinium bromide, Aclidinium bromide/formoterol fumarate, fluticasone furoate/umeclidinium/vilanterol, Ipratropium, Olodaterol/tiotropium bromide and 5 more. Compare all 11 Muscarinic acetylcholine receptor (M3) drugs
This mechanism is crowded: 23 other tracked programmes target it, none of them ahead of this one.
This drug's own stage for Chronic Obstructive Pulmonary Disease: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Glycopyrrolate / Formoterol Fumarate (Bevespi Aerosphere): this drug | Approved | Small molecule | Beta-2 adrenergic receptor, Muscarinic acetylcholine receptor (M3) | Weak signal | Featured results are non-efficacy only in this race | |
| Aclidinium Bromide (Tudorza Pressair) | Approved | Small molecule | Muscarinic acetylcholine receptor (M3) | Partial signal | NCT03022097: Change from baseline in morning pre-dose (trough) FEV1 at Week 24, aclidinium bromide 400 μg vs placebo: LS mean difference 0.134 L (p<0.001); AB 400 μg 0.050 L vs placebo -0.084 L. NCT00891462: Change From Baseline in Morning Pre-dose Forced Expiratory Volume in 1 Second (FEV1) (Change from Baseline to 12 weeks): Aclidinium Bromide, 200µg 0.062 L (Standard Error 0.015) | Aclidinium Bromide, 400µg 0.099 L (Standard Error 0.015) vs Placebo -0.025 L (Standard Error 0.015) | |
| Aclidinium Bromide / Formoterol Fumarate (Duaklir Pressair) | ApprovedUS marketing discontinued | Small molecule | Muscarinic acetylcholine receptor (M3), Beta-2 adrenergic receptor | Partial signal | NCT03022097: Change From Baseline in 1-hour Morning Post Forced Expiratory Volume in 1 Second (FEV1) (Week 24, 1-hour morning post-dose): AB/FF 400/12 μg 0.248 Litres (Standard Error 0.013) vs AB 400 μg 0.156 Litres (Standard Error 0.013) | FF 12 μg 0.138 Litres (Standard Error 0.013) | Placebo -0.05 Litres (Standard Error 0.013) NCT02796677: Week 24, AB/FF 400/12 ug: 1-hour post-dose FEV1 vs aclidinium 400 ug +0.084 L (95% CI 0.051 to 0.117), p<0.0001; trough FEV1 vs formoterol 12 ug +0.055 L (95% CI 0.023 to 0.088), p=0.0009. Monotherapy primary: aclidinium vs tiotropium trough FEV1 +0.007 L (95% CI -0.021 to 0.035), non-inferior at the -50 mL margin (CT.gov posted results). | |
| Albuterol (Armstrong Albuterol HFA) | Approved(overall) | Small molecule | Beta-2 adrenergic receptor | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Albuterol (Ventolin) | Approved(overall) | Small molecule | Beta-2 adrenergic receptor | Weak signal(overall) | No reviewed efficacy summary in this indication | |
| Albuterol / Budesonide (Airsupra) | Approved(overall) | Combination | Beta-2 adrenergic receptor, Glucocorticoid receptor | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Albuterol Sulfate (Amphastar) | Approved(overall) | Small molecule | Beta-2 adrenergic receptor | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Albuterol Sulfate (Proventil HFA) | Approved(overall) | Small molecule | Beta-2 adrenergic receptor | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Budesonide / Formoterol Fumarate (SYMBICORT) | Approved | Combination | Glucocorticoid receptor; Beta-2 adrenergic receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Budesonide / Glycopyrrolate / Formoterol Fumarate (Breztri Aerosphere) | Approved | Small molecule | Glucocorticoid receptor; Muscarinic M3; Beta-2 adrenergic | Reliable signal | NCT02465567: Rate of moderate/severe COPD exacerbations: PT010 (the trial's investigational triple therapy) reduced the rate by 24% vs glycopyrronium/formoterol fumarate (PT003) (p<0.001), and by 13% vs budesonide/formoterol fumarate (PT009) (p=0.003) NCT02497001: Primary 1, FEV1 AUC0-4 at week 24, BGF MDI vs BFF MDI: LS mean difference 116 mL (95% CI 80 to 152; p<0.0001), met. Primary 2, change from baseline in morning pre-dose trough FEV1 at week 24, BGF MDI vs GFF MDI: 13 mL (95% CI -9 to 36; p=0.2375), missed. Separate Europe/Canada analysis over 24 weeks: FEV1 AUC0-4 vs BFF MDI +104 mL (95% CI 77 to 131; p<0.0001) and vs BUD/FORM DPI +91 mL (p<0.0001); trough FEV1 vs GFF MDI +22 mL (95% CI 4 to 39; p=0.0139), all met. | |
| Dupilumab (Dupixent) | Approved | Monoclonal antibody | IL-4R-alpha | Partial signal | NCT04456673: Annualized Rate of Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Over the 52-week Treatment Period (Baseline (Day 1) to Week 52): Placebo 1.295 Exacerbation per participant-year (95% CI 1.048 to 1.6) | Dupilumab 300 mg q2w 0.859 Exacerbation per participant-year (95% CI 0.699 to 1.057) NCT03930732: Annualized Rate of Moderate or Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Over the 52-Week Treatment Period (Baseline (Day 1) to Week 52): Placebo 1.01 exacerbation per participant-year (95% CI 0.931 to 1.301) | Dupilumab 300 mg q2w 0.776 exacerbation per participant-year (95% CI 0.645 to 0.934) | |
| Ensifentrine (Ohtuvayre) | Approved | Small molecule | PDE3/PDE4 | Reliable signal | NCT05743075: Placebo-corrected change from baseline in FEV1 AUC0-12h at Week 12: +110 mL for ensifentrine (p<0.0001) NCT04535986: Least Square (LS) Mean Change From Baseline in Average Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve Over 12 Hours (AUC0-12h) at Week 12 (Baseline (pre-dose on Day 1) and Week 12): Ensifentrine 0.0611 liters (Standard Error 0.01825) vs Placebo -0.0256 liters (Standard Error 0.0195) | |
| Fluticasone Furoate / Umeclidinium / Vilanterol (Trelegy Ellipta) | Approved | Small molecule | Muscarinic acetylcholine receptor (M3), Beta-2 adrenergic receptor, Glucocorticoid receptor, Glucocorticoid receptor / Beta-2 adrenergic receptor / Muscarinic M3 receptor (ICS/LABA/LAMA triple combination) | Reliable signal | NCT02164513: Annual rate of on-treatment moderate/severe exacerbations: FF/UMEC/VI 0.91/yr vs FF/VI 1.07/yr (rate ratio 0.85, 95% CI 0.80-0.90, 15% reduction, p<0.001) vs UMEC/VI 1.21/yr (rate ratio 0.75, 95% CI 0.70-0.81, 25% reduction, p<0.001) NCT02345161: Co-primary 1, trough FEV1 change to week 24 (ITT): +142 mL with FF/UMEC/VI vs -29 mL with budesonide/formoterol (LS mean difference 171 mL, 95% CI 148 to 194; P<0.001), met. Co-primary 2, SGRQ total score change to week 24 (ITT): -6.6 vs -4.3 units (LS mean difference -2.2, 95% CI -3.5 to -1.0; P<0.001), met. Supportive week-52 analyses in the extension subset: FEV1 difference 179 mL (95% CI 131 to 226; P<0.001); SGRQ difference -2.7 (95% CI -5.5 to 0.2; P=0.065), not significant. | |
| Fluticasone Furoate / Vilanterol (Breo Ellipta) | Approved | Small molecule | Beta-2 adrenergic receptor, Glucocorticoid receptor, Glucocorticoid receptor / Beta-2 adrenergic receptor | Partial signal | NCT01313676: Number of Participants With Death (Both on and Off Treatment) Due to Any Cause, Time up to or on the Pre-determined Common End Date (From the date of randomization until date of death due to any cause (average of 2 study years)): Placebo — Dead: 275 Participants; Alive: 3832 Participants; Unknown: 4 Participants | Fluticasone Furoate 100 µg — Dead: 251 Participants; Alive: 3884 Participants; Unknown: 0 Participants | Vilanterol 25 µg — Dead: 265 Participants; Alive: 3853 Participants; Unknown: 0 Participants | Fluticasone Furoate/Vilanterol 100/25 µg — Dead: 246 Participants; Alive: 3874 Participants; Unknown: 1 Participants missed | |
| Fluticasone Propionate / Salmeterol (Advair Diskus) | Approved | Small molecule | Glucocorticoid receptor / Beta-2 adrenergic receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Fluticasone Propionate / Salmeterol (Advair HFA) | Approved(overall) | Combination | Glucocorticoid receptor / Beta-2 adrenergic receptor, Beta-2 adrenergic receptor, Glucocorticoid receptor | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Ipratropium | Approved | Small molecule | Muscarinic acetylcholine receptor (M3) | not yet graded | No reviewed efficacy summary in this indication | |
| Ipratropium / Albuterol | Approved | Small molecule | Muscarinic M3 receptor / Beta-2 adrenergic receptor (combination) | not yet graded | No reviewed efficacy summary in this indication | |
| Mepolizumab (Nucala) | Approved | Monoclonal antibody | IL-5, Interleukin-5 (IL-5), ligand-neutralizing | Partial signal | NCT04133909: Annualized Rate of Moderate or Severe Exacerbations (Up to Week 104): Mepolizumab 100 mg 0.8 Exacerbations per year (95% CI 0.7 to 0.91) | Placebo 1.01 Exacerbations per year (95% CI 0.89 to 1.15) | |
| Olodaterol | Approved | Small molecule | Beta-2 adrenergic receptor | Reliable signal | NCT00782210: FEV1 AUC0-3h response at Day 85 (Week 12), difference from placebo: olodaterol 5 mcg +0.172 L (SE 0.019), P<0.0001; olodaterol 10 mcg +0.176 L (SE 0.019), P<0.0001 (study 1222.11, n=624). NCT00796653: Week 24, olodaterol 5 and 10 ug vs placebo: FEV1 AUC0-3h +0.129 and +0.154 L (both p<0.0001); trough FEV1 +0.053 L (p=0.0055) and +0.069 L (p=0.0003); TDI focal score in this study +0.402 (p=0.1999) and +0.419 (p=0.1818), not significant; TDI in the combined analysis +0.509 (p=0.0270) and +0.525 (p=0.0203) (CT.gov posted results). | |
| Olodaterol / Tiotropium Bromide | Approved | Small molecule | Muscarinic acetylcholine receptor (M3), Beta-2 adrenergic receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Revefenacin (Yupelri) | Approved | Small molecule | Muscarinic receptors (antagonist) | Reliable signal | NCT05046795: Trough FEV1 on Day 85 (Baseline and Day 85): Revefenacin Inhalation Solution 175 mcg QD. 55.12 mL (Standard Error 23.974) vs Placebo Inhalation Solution QD. -95.78 mL (Standard Error 24.504) NCT02459080: Study 0126: trough FEV1 change at day 85 vs placebo +79 mL with revefenacin 88 µg (p=0.0003) and +146 mL with revefenacin 175 µg (p<0.0001). | |
| Roflumilast (Daliresp) | Approved | Small molecule | PDE4 | not yet graded | No reviewed efficacy summary in this indication | |
| Salmeterol (DISKUS) | Approved | Small molecule | Beta-2 adrenergic receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Tiotropium Bromide | Approved | Small molecule | Muscarinic acetylcholine receptor (M3) | Partial signal | NCT02172287: Primary 1, trough (predose morning) FEV1 change at 6 months vs placebo: tiotropium +0.14 L, salmeterol +0.09 L (tiotropium vs salmeterol p<0.01), met. Primary 2, TDI focal score at 6 months: tiotropium +1.02 units vs placebo (p=0.01), met; salmeterol +0.24 units, not significant. | |
| Umeclidinium (Incruse Ellipta) | Approved | Small molecule | Muscarinic acetylcholine receptor (M3) | Reliable signal | NCT02184611: Change from baseline in trough FEV1 at Day 169 (primary endpoint): UMEC 62.5 mcg vs placebo, LS mean treatment difference 154 mL (95% CI 113, 194; p<0.001) NCT01387230: Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) on Day 85 (Baseline and Day 85): Placebo -0.007 Liters (Standard Error 0.028) | UMEC 62.5 µg 0.12 Liters (Standard Error 0.0257) | UMEC 125 µg 0.145 Liters (Standard Error 0.0268) | |
| Umeclidinium / Vilanterol | Approved | Small molecule | Muscarinic acetylcholine receptor (M3), Beta-2 adrenergic receptor | Reliable signal | NCT01777334: Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) on Day 169 (Week 24) (Baseline and Day 169): UMEC/VI 62.5/25 µg 0.205 Liters (Standard Error 0.0114) vs TIO 18 µg 0.093 Liters (Standard Error 0.0115) NCT01716520: Change From Baseline (BL) in Weighted Mean (WM) 0-6 Hour Forced Expiratory Volume in One Second (FEV1) Obtained Post-dose at Day 14 of Each Treatment Period (TP) by Response Type (Baseline and Day 14 of each treatment period (up to study day 83)): UMEC/VI 62.5/25 µg — Responder to UMEC, n=90, 90, 88: 0.337 Liters (Standard Error 0.0166); Responder to VI, n=99, 102, 100: 0.331 Liters (Standard Error 0.0148); Responder to Neither, n=36, 37, 36: 0.13 Liters (Standard Error 0.0243) vs UMEC 62.5 µg — Responder to UMEC, n=90, 90, 88: 0.216 Liters (Standard Error 0.0166); Responder to VI, n=99, 102, 100: 0.189 Liters (Standard Error 0.015); Responder to Neither, n=36, 37, 36: 0.077 Liters (Standard Error 0.0243) | VI 25 µg — Responder to UMEC, n=90, 90, 88: 0.201 Liters (Standard Error 0.0167); Responder to VI, n=99, 102, 100: 0.233 Liters (Standard Error 0.0147); Responder to Neither, n=36, 37, 36: 0.057 Liters (Standard Error 0.024) | |
| Astegolimab | Phase 3 | Monoclonal antibody | ST2 (IL1RL1) | Partial signal | NCT05595642: ARNASA (NCT05595642), primary endpoint annualized COPD exacerbation rate (AER) at 52 weeks: astegolimab showed a numerical 14.5% reduction vs placebo, not statistically significant missed NCT05037929: Annualized COPD exacerbation rate reduced by a statistically significant 15.4% vs placebo at 52 weeks with every-two-weeks dosing | |
| Beclomethasone Dipropionate / Formoterol Fumarate | Phase 3 | Small molecule | Glucocorticoid receptor; β2-adrenergic receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Beclomethasone Dipropionate / Formoterol Fumarate / Glycopyrrolate (Trimbow) | Phase 3 | Small molecule | Glucocorticoid receptor / Beta-2 adrenergic receptor / Muscarinic M3 receptor (ICS/LABA/LAMA triple combination) | Reliable signal | No reviewed efficacy summary in this indication | |
| Depemokimab | Phase 3 | Monoclonal antibody | IL-5 | not yet graded | No reviewed efficacy summary in this indication | |
| Felcorekibart | Phase 3 | Monoclonal antibody | TSLP | not yet graded | No reviewed efficacy summary in this indication | |
| Fenoterol | Phase 3(overall) | Small molecule | Beta-2 adrenergic receptor | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| HSK39004 | Phase 3 | Small molecule | Phosphodiesterase 3 and Phosphodiesterase 4 (PDE3/PDE4) | not yet graded | No reviewed efficacy summary in this indication | |
| Lunsekimig | Phase 3 | Antibody-derived scaffold | TSLP + IL-13 | not yet graded | No reviewed efficacy summary in this indication | |
| Oxitropium Bromide (Ba253BINEB) | Phase 3(overall) | Small molecule | Muscarinic acetylcholine receptor (M3) | Weak signal(overall) | No reviewed efficacy summary in this indication | |
| REGEND001 | Phase 3 | Cell therapy | Airway epithelial regeneration (autologous basal cells) | Partial signal | No reviewed efficacy summary in this indication | |
| Salbutamol HFA-152a | Phase 3(overall) | Small molecule | Beta-2 adrenergic receptor | Weak signal(overall) | No reviewed efficacy summary in this indication | |
| Tezepelumab (Tezspire) | Phase 3 | Monoclonal antibody | TSLP, Thymic stromal lymphopoietin (TSLP), ligand-neutralizing | not yet graded | No reviewed efficacy summary in this indication | |
| Tilrekimig | Phase 3 | Multispecific antibody | IL-4/IL-13/TSLP | not yet graded | No reviewed efficacy summary in this indication | |
| Tozorakimab | Phase 3 | Monoclonal antibody | IL-33 | Partial signal | NCT06040086: Primary endpoint met: statistically significant reduction in the annualised rate of moderate-to-severe COPD exacerbations in former smokers and the overall population (MIRANDA, AstraZeneca, 2026-04-20). NCT05158387: Primary endpoint met: tozorakimab reduced the annualised rate of moderate-to-severe COPD exacerbations vs placebo in former smokers and the overall population (TITANIA, 2026-03-27). | |
| TQC3721 | Phase 3 | Small molecule | PDE3/PDE4 | Partial signal | NCT06527144: Primary endpoint, change in peak FEV1 at week 4 vs placebo: 3 mg +100 mL (95% CI 41 to 159; P = .0011); 6 mg +147 mL (95% CI 93 to 201; P < .0001) (PACER-II, CHEST 2026). | |
| Vilanterol | Phase 3(overall) | Small molecule | Beta-2 adrenergic receptor | Partial signal(overall) | NCT00519376: Single-dose crossover safety study in COPD; all 15 registered primaries were safety measures (adverse events, haematology, chemistry, vital signs, ECG) with no formal test. Any adverse event: placebo 2/19, GW642444M 25 µg 1/20, 50 µg 2/19, 100 µg 0/8, GW642444H 100 µg 0/12; no serious adverse events (CT.gov posted results). | |
| Glycopyrronium (PT001) | Phase 2/3(overall) | Small molecule | Muscarinic acetylcholine receptor (M3) | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Stapokibart | Phase 2/3 | Monoclonal antibody | IL-4R-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| 9MW1911 | Phase 2 | Monoclonal antibody | IL-33/ST2, ST2 (IL1RL1) | Weak signal | Featured results are safety only in this race | |
| Alvelestat | Phase 2 | Small molecule | Neutrophil elastase | Partial signal | NCT03636347: Blood neutrophil elastase activity reduced from baseline: -83.5% (SD 56.4) at alvelestat 120mg (p=0.023) and -93.3% (SD 41.0) at 240mg (p<0.001); both doses significant vs placebo (p<0.01 and p<0.001 respectively). | |
| AZD6793 | Phase 2 | Small molecule | IRAK4 | not yet graded | No reviewed efficacy summary in this indication | |
| Brenipatide | Phase 2 | Peptide | GLP-1/GIP receptor (dual) | not yet graded | No reviewed efficacy summary in this indication | |
| CM512 | Phase 2 | Multispecific antibody | TSLP + IL-13 | not yet graded | No reviewed efficacy summary in this indication | |
| Dexpramipexole | Phase 2 | Small molecule | Eosinophil maturation/survival (mitochondrial) | not yet graded | No reviewed efficacy summary in this indication | |
| Glasmacinal | Phase 2 | Small molecule | Airway epithelial barrier integrity | Partial signal | NCT05516316: Primary endpoint (BALF IL-8 after inhaled LPS challenge, 375 mg EP395 daily for 3 weeks vs placebo) not met. BALF IL-6, TNF-alpha, MIP-1alpha, MIP-1beta and MCP-1 were lower and IL-33, IL-8, IL-1beta, neutrophil elastase and myeloperoxidase higher with EP395 (none statistically significant). Serum SP-D rose with EP395 (mean 148.8 to 183.0 ng/mL at 24 h, p=0.0007) but not with placebo. missed | |
| HRS-9821 | Phase 2 | Small molecule | PDE3/PDE4 | Weak signal | No reviewed efficacy summary in this indication | |
| Ocankitug | Phase 2 | Monoclonal antibody | TSLP | not yet graded | No reviewed efficacy summary in this indication | |
| PBF-680 | Phase 2 | — | Adenosine A1 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Pegtarazimod | Phase 2 | Peptide | Complement C1q / neutrophil effectors (myeloperoxidase, NETosis) | not yet graded | No reviewed efficacy summary in this indication | |
| Rademikibart | Phase 2 | Monoclonal antibody | IL-4R-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| RC1416 | Phase 2 | Multispecific antibody | IL-4 / IL-5 / IL-13 | not yet graded | No reviewed efficacy summary in this indication | |
| RSS0343 | Phase 2 | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| Solizmestrocel | Phase 2 | Cell therapy | Regenerative/anti-inflammatory (MSC) | Weak signal | No reviewed efficacy summary in this indication | |
| Verekitug | Phase 2 | Monoclonal antibody | TSLP receptor | not yet graded | No reviewed efficacy summary in this indication | |
| WIN378 | Phase 2 | Monoclonal antibody | TSLP | not yet graded | No reviewed efficacy summary in this indication | |
| XKH001 | Phase 2 | Monoclonal antibody | IL-25 | not yet graded | No reviewed efficacy summary in this indication | |
| KIT2014 | Phase 1/2 | Peptide | PDE3/PDE4 | not yet graded | No reviewed efficacy summary in this indication | |
| APG808 | Phase 1(overall) | Monoclonal antibody | IL-4R-alpha | not yet graded | No reviewed efficacy summary in this indication | |
| BBT002 | Phase 1 | Multispecific antibody | IL-4Ralpha / IL-5 | not yet graded | No reviewed efficacy summary in this indication | |
| Frevecitinib | Phase 1 | Small molecule | JAK1/2/3/TYK2 | Weak signal | No reviewed efficacy summary in this indication | |
| GDC-6988 | Phase 1 | Small molecule | TMEM16A (Anoctamin-1) calcium-activated chloride channel | not yet graded | No reviewed efficacy summary in this indication | |
| GSK3862995 | Phase 1 | Monoclonal antibody | IL-33 | not yet graded | No reviewed efficacy summary in this indication | |
| PUR1800 | Phase 1 | Small molecule | Narrow-spectrum kinase (p38/Syk-family) | not yet graded | No reviewed efficacy summary in this indication | |
| REGEND007 | Phase 1 | Cell therapy | Airway basal layer stem cells | not yet graded | No reviewed efficacy summary in this indication | |
| Ensifentrine / Glycopyrrolate | —(overall) | Small molecule | — | not yet graded | No reviewed efficacy summary in this indication | |
| GSK6759821 | —(overall) | RNA / oligonucleotide | — | not yet graded | No reviewed efficacy summary in this indication | |
| RG6527 | —(overall) | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| Amphastar A006 | Discontinued | — | Beta-2 adrenergic receptor | Partial signal(overall) | No reviewed efficacy summary in this indication | |
| Itepekimab | Discontinued | Monoclonal antibody | IL-33 | Partial signal | NCT04701983: Annualized rate of moderate/severe AECOPD, reduction vs placebo at Week 52: 27% (every-2-week dosing arm), statistically significant primary endpoint met NCT04751487: AERIFY-2 (NCT04751487), annualized rate of moderate/severe AECOPD exacerbations vs placebo at Week 52 (the primary-endpoint timepoint): 2% reduction with itepekimab every-2-weeks, 12% reduction with itepekimab every-4-weeks; neither reached statistical significance missed | |
| Navafenterol | Discontinued | — | Muscarinic receptors and beta-2 adrenergic receptors, Muscarinic receptors (M1-M3) and beta-2 adrenergic receptor | Reliable signal | No reviewed efficacy summary in this indication |
Compare side by side
5 further pairs are tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
No upcoming readouts on record for this asset.